Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
INTEGRATIVE NETWORK MODELLING OF DRUG RESPONSES IN CANCER FOR REVEALING MECHANISM OF ACTION
Download
seymaunsalbeyge-thesis.pdf
Date
2021-9-6
Author
Ünsal Beyge, Şeyma
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
388
views
683
downloads
Cite This
Classification of cancer drugs is crucial for drug repurposing since the cost and innovation deficit make new drug development processes challenging. Heterogeneity of cancer causes drug classification purely based on known mechanism of action (MoA) and the list of target proteins to be insufficient. Multi-omic data integration is necessary for a systems biology perspective to understand molecular mechanisms and interactions between cellular entities underlying the disease. This study integrates drug-target interaction data with transcriptomics and phosphoproteomic data of perturbed cell lines to model drug and cell-specific subnetworks. Total 250 networks are reconstructed, including 70 small molecule drugs on six cell lines. Similarities of reconstructed networks are quantitatively calculated using a topology-based network comparison measure which scores the separation of networks using the shortest paths between network nodes. Different drugs with similar omic outcomes on variable cell lines are revealed with the aid of separation scores. Moreover, the effect of drugs on variable cell lines is discovered together with the impact of target selectivity of drugs within the same MoA group. Functional analysis of reconstructed networks for their enriched cellular pathways further indicated that drugs with different chemical structures and MoA might induce common signaling cascades. As omics data integration coupled network modeling reveals modulated pathways for specific conditions, the methodology of this study is applicable to different drug-disease research areas. Prediction of drug combinations for a given disease and inference of drug similarity based on cell line sensitivity are two applications presented in this study.
Subject Keywords
Network reconstruction
,
protein-protein interactions
,
omics
,
drug repurposing
,
data integration
URI
https://hdl.handle.net/11511/93052
Collections
Graduate School of Informatics, Thesis
Suggestions
OpenMETU
Core
Predicting the binding affinities of drug-protein interaction by analyzing the images of binding sites
Erdaş, Özlem; Alpaslan, Ferda Nur; Büyükbingöl, Erdem; Department of Computer Engineering (2013)
Analysis of protein-ligand interactions plays an important role in designing safe and efficient drugs, contributing to drug discovery and development. Recently, machine learning methods have been found useful in drug design, which utilize intelligent techniques to predict unknown protein-ligand interactions by learning from specific properties of known protein-ligand interactions. The aim of this thesis is to propose a novel computational model, Compressed Images for Affinity Prediction (CIFAP), to predict ...
Providing Semantic Interoperability Between Clinical Care and Clinical Research Domains
Laleci, Gokce Banu; Yuksel, Mustafa; Doğaç, Asuman (2013-03-01)
Improving the efficiency with which clinical research studies are conducted can lead to faster medication innovation and decreased time to market for new drugs. To increase this efficiency, the parties involved in a regulated clinical research study, namely, the sponsor, the clinical investigator and the regulatory body, each with their own software applications, need to exchange data seamlessly. However, currently, the clinical research and the clinical care domains are quite disconnected because each use ...
Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line
Mutlu, Pelin; Gündüz, Ufuk (Elsevier BV, 2012-4)
Drug resistance remains a major obstacle to the successful use of chemotherapeutic drugs for many types of cancers including multiple myeloma. It is becoming increasingly apparent that tumor microenvironment could provide a shelter to malignant plasma cells that allow their survival after initial drug exposure. This study demonstrates alterations in gene expression levels of several extracellular matrix (ECM) components in prednisone, vincristine and melphalan-resistant RPMI-8226 myeloma cells. Resistant RP...
Investigation of the Therapeutic Effects of Palbociclib Conjugated Magnetic Nanoparticles on Different Types of Breast Cancer Cell Lines
Parsian, Maryam; MUTLU, PELİN; Taghavi Pourianazar, Negar; Yalcin Azarkan, Serap; Gündüz, Ufuk (2023-01-01)
Introduction: Drug targeting and controlled drug release systems in cancer treatment have many advantages over conventional chemotherapy in terms of limiting systemic toxicity, side effects, and overcoming drug resistance. Methods and Results: In this paper, fabricating nanoscale delivery system composed of magnetic nanoparticles (MNPs) covered with poly-amidoamine (PAMAM) dendrimers and using its advantages were fully used to help the chemotherapeutic drug, Palbociclib, effectively reach tumors, specifical...
CpG oligodeoxynucleotide- loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells
Pourianazar, Negar Taghavi; Gündüz, Ufuk (2016-03-01)
One major application of nanotechnology in cancer treatment involves designing nanoparticles to deliver drugs, oligonucleotides, and genes to cancer cells. Nanoparticles should be engineered so that they could target and destroy tumor cells with minimal damage to healthy tissues. This research aims to develop an appropriate and efficient nanocarrier, having the ability of interacting with and delivering CpG-oligodeoxynucleotides (CpG-ODNs) to tumor cells. CpG-ODNs activate Toll-like receptor 9 (TLR9), which...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
Ş. Ünsal Beyge, “INTEGRATIVE NETWORK MODELLING OF DRUG RESPONSES IN CANCER FOR REVEALING MECHANISM OF ACTION,” Ph.D. - Doctoral Program, Middle East Technical University, 2021.